Aspaveli - 0 - Aspaveli - NO

Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1

See more with Aspaveli®

Patient burden

Up to 85% of patients receiving C5i treatment do not achieve normal-like Hb levels2

Find Out More
Mechanism of action

Aspaveli is the first and only C3i addressing both IVH and EVH1,3

FIND OUT MORE
Patient outcomes

Aspaveli empowers patients by minimising debilitating fatigue and improving physical and social functioning4,5

FIND OUT MORE
Self-administration

Aspaveli is the first subcutaneous treatment for PNH that can be self-administered to suit patients' lifestyles6

FIND OUT MORE

References

1. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024, pkt. 4.1. 2. Risitano AM and Peffault de Latour R. BJH. 2022;196:288–303. 3. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024, pkt. 5.1. 4. Hillmen P, Szer J, Weitz IC, et al. N Engl J Med. 2021;384:1028–1037. 5. Peffault de Latour R, Szer J, Weitz IC, et al. Lancet Haematol. 2022;9:e648–659. 6. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024, pkt. 4.2.

PP-20367
Other sites
expand_less